solid tumors

Study of onset, progression and treatment of hematological and solid tumors, focusing on chronic lymphocytic leukemia, glioma, neuroblastoma, colorectal, pancreatic, ovarian and breast cancer


The tumor microenvironment is an important modulator of malignant growth. A deep understanding of the complex relationships occurring at the tumor site among stromal cells, immune cells, and soluble factors could provide important information on the recruitment of immune cells and the possible impairment of their anti-tumor properties. Elucidating the complex network in the tumor microenvironment can be crucial for understanding the mechanisms of tumor escape from immune recognition, and for developing new therapeutic strategies

Hematopoietic Stem Cell Transplantation (HSCT) and immunotherapy are important instruments to fight hematological malignancies and solid tumors. Immunotherapeutic approaches include the use of monoclonal antibodies (mAbs) targeting tumor-associated antigens or blocking immune checkpoints (ICB), and chimeric antigen receptor (CAR)-engineered T or NK cells.